S. M. Gyulakhmedova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
S. M. Gyulakhmedova has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- A. A. Druzhinina
Scientific Centre for Expert Evaluation of Medicinal Products
3 shared publications - A. O. Lovkova
Scientific Centre for Expert Evaluation of Medicinal Products
2 shared publications - E. O. Zhuravleva
Scientific Centre for Expert Evaluation of Medicinal Products
2 shared publications - N. Yu. Velts
Scientific Centre for Expert Evaluation of Medicinal Products
2 shared publications Н. Ю. Вельц
Федеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской Федерации
2 shared publications- A. A. Chistokhina
Scientific Centre for Expert Evaluation of Medicinal Products
1 shared publication
Latest Publications
- Open Access
- 29 September 2025
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 13 (3) , 290-299
Therapeutic Potential of Myo-Inositol in Male Infertility: Correction of Spermatogenesis Parameters and Oxidative Stress (Review)
INTRODUCTION. Male infertility, in particular reproductive system deficiency, is often associated with oxidative stress. Myo-inositol antioxidant properties are essential for various biochemical and cellular processes in spermatozoa; for example, they contribute to mitochondrial function and sperm motility. This creates an opportunity to use inositol in the complex infertility treatment of various aetiology, including oligoasthenoteratozoospermia, asthenozoospermia, and in assisted reproductive technologies.AIM. This study aimed to evaluate the possibility and effectiveness of using inositol for spermatogenesis restoration in male reproductive dysfunction caused by oxidative stress.DISCUSSION. Oxidative stress damages sperm cell membrane, causes mitochondrial dysfunction, and affects DNA. Studies show that myo-inositol positively impacts spermatogenesis due to its antioxidant properties and activation of mitochondrial metabolism. It promotes ATP production, reduces oxidative damage markers, decreases DNA fragmentation and improves sperm morphology. Moreover, myo-inositol increases cellular testosterone, optimises actin — globulin binding, thus enhancing sperm motility, and modulates intracellular calcium concentrations necessary for oxidative metabolism and ATP synthesis. Clinical studies have shown that inositol increases overall sperm motility by 20–30%; progressive motility — up to 40%; fertilisation rate — by 10–15%, and reduces DNA fragmentation by 3–5%. Myo-inositol used for sperm cryopreservation reduces reactive oxygen and apoptosis, maintains mitochondrial membrane potential, and increases oxidative phosphorylation efficiency by 6–15%.CONCLUSIONS. Myo-inositol is a promising therapeutic compound for treating male infertility of various aetiology, including oligoasthenoteratozoospermia, asthenozoospermia, and for preparing sperm in assisted reproductive technologies. Also, due to its antioxidant properties, myo-inositol can be recommended in suspected or confirmed oxidative damage to sperm. However, large controlled trials are needed to confirm positive effect of myo-inositol on male reproductive function.
- 29 September 2025
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 13 (3) , 290-299
Open AccessTherapeutic Potential of Myo-Inositol in Male Infertility: Correction of Spermatogenesis Parameters and Oxidative Stress (Review)
INTRODUCTION. Male infertility, in particular reproductive system deficiency, is often associated with oxidative stress. Myo-inositol antioxidant properties are essential for various biochemical and cellular processes in spermatozoa; for example, they contribute to mitochondrial function and sperm motility. This creates an opportunity to use inositol in the complex infertility treatment of various aetiology, including oligoasthenoteratozoospermia, asthenozoospermia, and in assisted reproductive technologies.AIM. This study aimed to evaluate the possibility and effectiveness of using inositol for spermatogenesis restoration in male reproductive dysfunction caused by oxidative stress.DISCUSSION. Oxidative stress damages sperm cell membrane, causes mitochondrial dysfunction, and affects DNA. Studies show that myo-inositol positively impacts spermatogenesis due to its antioxidant properties and activation of mitochondrial metabolism. It promotes ATP production, reduces oxidative damage markers, decreases DNA fragmentation and improves sperm morphology. Moreover, myo-inositol increases cellular testosterone, optimises actin — globulin binding, thus enhancing sperm motility, and modulates intracellular calcium concentrations necessary for oxidative metabolism and ATP synthesis. Clinical studies have shown that inositol increases overall sperm motility by 20–30%; progressive motility — up to 40%; fertilisation rate — by 10–15%, and reduces DNA fragmentation by 3–5%. Myo-inositol used for sperm cryopreservation reduces reactive oxygen and apoptosis, maintains mitochondrial membrane potential, and increases oxidative phosphorylation efficiency by 6–15%.CONCLUSIONS. Myo-inositol is a promising therapeutic compound for treating male infertility of various aetiology, including oligoasthenoteratozoospermia, asthenozoospermia, and for preparing sperm in assisted reproductive technologies. Also, due to its antioxidant properties, myo-inositol can be recommended in suspected or confirmed oxidative damage to sperm. However, large controlled trials are needed to confirm positive effect of myo-inositol on male reproductive function.
- Open Access
- 13 October 2023
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 11 (4) , 463-472
Analysis of Errors Identified during Regulatory Review of Risk Management Plans Submitted as Part of Registration Dossiers
Scientific relevance. On 6 December 2022, an updated version of the Rules for Good Pharmacovigilance Practice of the Eurasian Economic Union (EAEU GVP) came into force. The greatest changes were made to the requirements for pharmacovigilance documents, particularly the risk management plan (RMP). In practice, the changed EAEU GVP has resulted in multiple errors, creating the need to thoroughly analyse their structure and causes and to develop recommendations for their prevention.Aim. This study aimed to identify, analyse, and collate inconsistencies between the information submitted by marketing authorisation holders in their RPMs and the updated EAEU GVP requirements.Materials and methods. The Scientific Centre for Expert Evaluation of Medicinal Products analysed 50 RMPs received after 6 December 2022 as part of registration dossiers aimed to support marketing authorisation applications and/or align the registration dossiers with the EAEU requirements.Results. The errors made by applicants when preparing RMPs were categorised according to their influence on the interpretation of a medicinal product’s safety profile. The errors leading to incorrect safety profile interpretations were considered type 1 errors (63% of the cases). The errors affecting the perception of the RMP but not the interpretation of the safety profile (e.g., grammatical errors, notes and comments by applicants, incorrect translation of terms) were deemed type 2 errors (37% of the cases). The majority of EAEU GVP noncompliance cases were detected in Part II of the RMP, the section providing the most information on the safety profile of a medicinal product.Conclusions. There are several ways to improve the quality of RMP preparation. The information included in the RMP should be compared with the information provided in the registration dossier. The RMP should be incorporated into the integrated pharmaceutical quality system according to the requirements of good practices.A responsible employee of the marketing authorisation holder’s quality assurance system should control the final RMP version. Employees of pharmacovigilance departments should receive regular training.
- 13 October 2023
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 11 (4) , 463-472
Open AccessAnalysis of Errors Identified during Regulatory Review of Risk Management Plans Submitted as Part of Registration Dossiers
Scientific relevance. On 6 December 2022, an updated version of the Rules for Good Pharmacovigilance Practice of the Eurasian Economic Union (EAEU GVP) came into force. The greatest changes were made to the requirements for pharmacovigilance documents, particularly the risk management plan (RMP). In practice, the changed EAEU GVP has resulted in multiple errors, creating the need to thoroughly analyse their structure and causes and to develop recommendations for their prevention.Aim. This study aimed to identify, analyse, and collate inconsistencies between the information submitted by marketing authorisation holders in their RPMs and the updated EAEU GVP requirements.Materials and methods. The Scientific Centre for Expert Evaluation of Medicinal Products analysed 50 RMPs received after 6 December 2022 as part of registration dossiers aimed to support marketing authorisation applications and/or align the registration dossiers with the EAEU requirements.Results. The errors made by applicants when preparing RMPs were categorised according to their influence on the interpretation of a medicinal product’s safety profile. The errors leading to incorrect safety profile interpretations were considered type 1 errors (63% of the cases). The errors affecting the perception of the RMP but not the interpretation of the safety profile (e.g., grammatical errors, notes and comments by applicants, incorrect translation of terms) were deemed type 2 errors (37% of the cases). The majority of EAEU GVP noncompliance cases were detected in Part II of the RMP, the section providing the most information on the safety profile of a medicinal product.Conclusions. There are several ways to improve the quality of RMP preparation. The information included in the RMP should be compared with the information provided in the registration dossier. The RMP should be incorporated into the integrated pharmaceutical quality system according to the requirements of good practices.A responsible employee of the marketing authorisation holder’s quality assurance system should control the final RMP version. Employees of pharmacovigilance departments should receive regular training.
- Open Access
- 5 October 2022
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 10 (3) , 259-268
Analysis of the Causes for Renal Dysfunction during Antibiotic Therapy in a Patient with Lyme Disease
Adverse drug reactions (ADRs) are recorded throughout the lifecycle of a medicinal product. In the post-marketing period, new ADRs are primarily identified via drug safety signals. In order to assess a signal and establish causality between an adverse drug reaction and a suspected medicinal product, it is necessary to evaluate the signal strength and quality.The aim of the study was to analyse the information submitted to Russian regulatory authorities by a patient and check it for a potential causal association of acute tubulointerstitial nephritis (ATIN) with the use of ceftriaxone and with the patient’s principal diagnosis, Lyme disease.Materials and methods: the authors analysed the patient’s submission received by the Ministry of Health of the Russian Federation in 2022 with a complaint that the treatment of Lyme disease with ceftriaxone had caused ATIN. The probability of a causal relationship between the medicinal product and the ADR was evaluated using the Naranjo algorithm.Results: according to the review of literature and the spontaneous reports collected in Pharmacovigilance 2.0, the database in the Automated Information System of the Russian Federal Service for Surveillance in Healthcare, both ceftriaxone and the underlying condition (Lyme disease) may cause renal abnormalities. Ceftriaxone is potentially nephrotoxic; it mainly affects the tubular system of the kidneys. Borreliosis may cause kidney damage as well; such damage manifests clinically as rapidly progressing and fatal damage to the glomeruli.Conclusions: the probability of a causal relationship between the development of ATIN in the complainant and the use of ceftriaxone was categorised as “possible”. However, the information available did not allow for establishing a definite relationship between kidney damage and the use of the medicinal product. Further monitoring of similar cases is necessary to minimise the risks of developing this pathology during treatment with ceftriaxone.
- 5 October 2022
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 10 (3) , 259-268
Open AccessAnalysis of the Causes for Renal Dysfunction during Antibiotic Therapy in a Patient with Lyme Disease
Adverse drug reactions (ADRs) are recorded throughout the lifecycle of a medicinal product. In the post-marketing period, new ADRs are primarily identified via drug safety signals. In order to assess a signal and establish causality between an adverse drug reaction and a suspected medicinal product, it is necessary to evaluate the signal strength and quality.The aim of the study was to analyse the information submitted to Russian regulatory authorities by a patient and check it for a potential causal association of acute tubulointerstitial nephritis (ATIN) with the use of ceftriaxone and with the patient’s principal diagnosis, Lyme disease.Materials and methods: the authors analysed the patient’s submission received by the Ministry of Health of the Russian Federation in 2022 with a complaint that the treatment of Lyme disease with ceftriaxone had caused ATIN. The probability of a causal relationship between the medicinal product and the ADR was evaluated using the Naranjo algorithm.Results: according to the review of literature and the spontaneous reports collected in Pharmacovigilance 2.0, the database in the Automated Information System of the Russian Federal Service for Surveillance in Healthcare, both ceftriaxone and the underlying condition (Lyme disease) may cause renal abnormalities. Ceftriaxone is potentially nephrotoxic; it mainly affects the tubular system of the kidneys. Borreliosis may cause kidney damage as well; such damage manifests clinically as rapidly progressing and fatal damage to the glomeruli.Conclusions: the probability of a causal relationship between the development of ATIN in the complainant and the use of ceftriaxone was categorised as “possible”. However, the information available did not allow for establishing a definite relationship between kidney damage and the use of the medicinal product. Further monitoring of similar cases is necessary to minimise the risks of developing this pathology during treatment with ceftriaxone.
- Open Access
- 1 July 2021
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 9 (2) , 103-105
Drug Safety Monitoring Information
Analysis of administrative decisions of foreign regulatory authorities on the recall of medicines and/or the need for changes in the instructions for their medical use due to changes in the safety profile, conducted by experts of the Scientific Centre for Expert Evaluation of Medicinal Products revealed 19 administrative decisions. These decisions contained information on the following medicines registered in Russia: amikacin, tobramycin, gentamicin, neomycin, ciprofloxacin, delafloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin, prulifloxacin, rufloxacin, сeftriaxone, ceftaroline, rifapentine, tigecycline, bacitracin, ertapenem, daptomycin, erythromycin, fosfomycin, ampicillin+sulbactam, chloroquine, hydroxychloroquine.
- 1 July 2021
- Published by SCEEMP in Safety and Risk of Pharmacotherapy
- Vol. 9 (2) , 103-105
Open AccessDrug Safety Monitoring Information
Analysis of administrative decisions of foreign regulatory authorities on the recall of medicines and/or the need for changes in the instructions for their medical use due to changes in the safety profile, conducted by experts of the Scientific Centre for Expert Evaluation of Medicinal Products revealed 19 administrative decisions. These decisions contained information on the following medicines registered in Russia: amikacin, tobramycin, gentamicin, neomycin, ciprofloxacin, delafloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, pefloxacin, prulifloxacin, rufloxacin, сeftriaxone, ceftaroline, rifapentine, tigecycline, bacitracin, ertapenem, daptomycin, erythromycin, fosfomycin, ampicillin+sulbactam, chloroquine, hydroxychloroquine.